spacer
home > > winter 2003 > hyperbaric oxygen therapy and diabetes
PUBLICATIONS


Hyperbaric Oxygen Therapy and Diabetes

Treatment and Benefits of Hyperbaric Oxygen Therapy

HBO therapy is the provision of oxygen at raised pressure. Oxygen (O2) behaves like a drug with response depending on the dose:
Air at 1 atmosphere gives a dose of 0.2 bar O2
100 per cent oxygen at 1 atmosphere gives a dose of 1 bar O2
100 per cent oxygen at 2.8 bar gives a dose of 2.8 bar O2 (that is 14 times the dose of O2 compared with air at 1 atmosphere)

Patients breathe the oxygen via a mask, hood or ventilator at pressures above 1 atmosphere (bar) and are treated in a recompression chamber, where they are accompanied by a doctor, nurse or attendant. The pressure in the chamber is raised with compressed air. The attendants will therefore breathe this air for most of the treatment duration, and at designated times they will have to breathe oxygen which lowers the risk of decompression illness.

Patients will receive between two and 40 treatments depending on the medical condition being treated. Typically patients with decompression illness or carbon monoxide poisoning may only require between one and three treatment sessions, while patients with difficult wounds may require up to 40. The pressure in the chamber is raised to between 2.4 and 2.8 bar, and each treatment will last from two to eight hours, again depending on the medical condition.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Sara Hasan, Hyperbaric Nurse Consultant, Peter Dodds, Manager, Hyperbaric Medicine Unit, and Phil Catling, Business Group Manager, Electro-Optic Systems at QinetiQ

Sara Hasan trained at St Mary's Hospital in Paddington. She has over 20 years' nursing experience, mostly in critical care, and joined the Hyperbaric Medicine Unit at Haslar in 1997 where she is a Hyperbaric Nurse Consultant.

Peter Dodds is responsible for the day-to-day running of the Hyperbaric Medicine Unit. His technical experience in this area goes back to 1980 when he first became involved in experimental diving programmes.

Phil Catling has over 30 years' experience in human factors and avionics systems R&D. He manages QinetiQ's diabetic retinopathy programme and is also active in progressing other health-related activities.

spacer
Sara Hasan
spacer
spacer
spacer
Peter Dodds
spacer
spacer
spacer
Phil Catling
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Janssen Announces Phase 1 Results for Bispecific Antibody Amivantamab in the Treatment of Patients with Advanced Non-Small Cell Lung Cancer Harbouring Exon 20 Insertion Mutations

BEERSE, BELGIUM, May 18, 2020 The Janssen Pharmaceutical Companies of Johnson & Johnson today announced results from the Phase 1 CHRYSALIS study evaluating amivantamab (JNJ-6372) in the treatment of patients with advanced non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) Exon 20 insertion mutations.[i] Amivantamab is an EGFR and MET-targeted bispecific antibody, which targets activating and resistance EGFR mutations, and MET pathway activation.[ii],[iii] Investigators assessed efficacy using overall response rate (ORR) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1), duration of response, as well as the safety profile of amivantamab,1 which were the basis of the U.S. Food and Drug Administration (FDA) Breakthrough Therapy Designation granted earlier this year.[iv]
More info >>

White Papers

Considerations for Choosing the Right Wearable Drug Delivery System

West Pharmaceutical Services, Inc.

For patients with chronic conditions, the use of injectable biologic therapies is on the rise. Biologics, while providing considerable therapeutic benefit, can also present several challenges for both drug manufacturers and patients. In particular, many biologics are highly viscous and others require large doses to be injected slowly over time. This can make it difficult to deliver a consistent dose every time, potentially impacting medication adherence.
More info >>

 
Industry Events

World Vaccine Congress Washington

27-29 September 2020, Walter E Washington Convention Center, Washington, US

The World Vaccine Congress is an award-winning series of conferences and exhibitions that have grown to become the largest and most established vaccine meeting of its kind across the globe. Our credibility is show through the prestigious scientific advisory board that spend months of hard work creating a new and topical agenda, year on year.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement